Literature DB >> 7988457

Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions.

T B Usdin1, T I Bonner, E Mezey.   

Abstract

Vasoactive intestinal polypeptide (VIP) has a variety of physiological effects. Pharmacological evidence suggesting that VIP acts via multiple receptors has been confirmed by the cloning of two VIP receptors (VIP1 and VIP2) with very different amino acid sequences. At both the VIP1 and the VIP2 receptor VIP, PHI, PACAP38, and PACAP27 have similar potency to each other. Only the VIP1 receptor is activated by secretin. The messenger RNAs (mRNAs) for the two receptors have completely different distributions as mapped by in situ hybridization histochemistry. VIP1 receptor mRNA is predominantly found in the lung, small intestine, thymus, and within the brain in the cerebral cortex and hippocampus. VIP2 receptor mRNA is present in a number of areas where VIP acts but VIP1 receptor mRNA is not present, including the stomach and testes. In the CNS VIP2 receptor mRNA is exclusively present in areas associated with neuroendocrine function, including several hypothalamic nuclei. In the periphery, it is also present in the pituitary and in pancreatic islets.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7988457     DOI: 10.1210/endo.135.6.7988457

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  75 in total

1.  The absence of VPAC2 leads to aberrant antibody production in Aspergillus fumigatus sensitized and challenged mice.

Authors:  Amali E Samarasinghe; Scott A Hoselton; Jane M Schuh
Journal:  Peptides       Date:  2010-10-13       Impact factor: 3.750

2.  Overexpression of the human VPAC2 receptor in the suprachiasmatic nucleus alters the circadian phenotype of mice.

Authors:  S Shen; C Spratt; W J Sheward; I Kallo; K West; C F Morrison; C W Coen; H M Marston; A J Harmar
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

3.  Spatiotemporal distribution of vasoactive intestinal polypeptide receptor 2 in mouse suprachiasmatic nucleus.

Authors:  Sungwon An; Connie Tsai; Julie Ronecker; Alison Bayly; Erik D Herzog
Journal:  J Comp Neurol       Date:  2012-08-15       Impact factor: 3.215

Review 4.  Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.

Authors:  Anthony J Harmar; Jan Fahrenkrug; Illana Gozes; Marc Laburthe; Victor May; Joseph R Pisegna; David Vaudry; Hubert Vaudry; James A Waschek; Sami I Said
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

5.  Antisecretory actions of a novel vasoactive intestinal polypeptide (VIP) antagonist in human and rat small intestine.

Authors:  Matthew R Banks; Michael J G Farthing; Patrick Robberecht; David E Burleigh
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

Review 6.  Vasoactive intestinal peptide and the mammalian circadian system.

Authors:  Andrew M Vosko; Analyne Schroeder; Dawn H Loh; Christopher S Colwell
Journal:  Gen Comp Endocrinol       Date:  2007-05-26       Impact factor: 2.822

7.  Molecular cloning and characterization of two pig vasoactive intestinal polypeptide receptors (VPAC1-R and VPAC2-R).

Authors:  Xiaping He; Fengyan Meng; Yajun Wang; Juan Li
Journal:  DNA Cell Biol       Date:  2014-02-12       Impact factor: 3.311

8.  Pituitary adenylate cyclase-activating polypeptide regulates brain-derived neurotrophic factor exon IV expression through the VPAC1 receptor in the amphibian melanotrope cell.

Authors:  Adhanet H Kidane; Eric W Roubos; Bruce G Jenks
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

9.  Central PACAP mediates the sympathetic effects of leptin in a tissue-specific manner.

Authors:  M Tanida; A Hayata; N Shintani; N Yamamoto; Y Kurata; T Shibamoto; D A Morgan; K Rahmouni; H Hashimoto
Journal:  Neuroscience       Date:  2013-02-27       Impact factor: 3.590

10.  Comparative effects of PACAP and VIP on pancreatic endocrine secretions and vascular resistance in rat.

Authors:  G Bertrand; R Puech; Y Maisonnasse; J Bockaert; M M Loubatières-Mariani
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.